{"prompt": "['Novartis', 'Confidential', 'Page 50', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '10.1.3', 'SAE reporting', 'To ensure patient safety, every SAE, regardless of causality, occurring after the patient has', 'provided informed consent and until 30 days following the last administration of study', 'treatment must be reported to Novartis safety within 24 hours of learning of its occurrence.', 'Detailed instructions regarding the submission process and requirements are to be found in the', 'Investigator folder provided to each site.', 'All follow-up information for the SAE including information on complications, progression of', 'the initial SAE and recurrent episodes must be reported as follow-up to the original episode', 'within 24 hours of the Investigator receiving the follow-up information. An SAE occurring at a', 'different time interval or otherwise considered completely unrelated to a previously reported', 'one must be reported separately as a new event.', \"If the SAE is not previously documented in the Investigator's Brochure or Package Insert (new\", 'occurrence) and is thought to be related to the study treatment, a Chief Medical Office and', 'Patient Safety Department associate may urgently require further information from the', 'Investigator for health authority reporting. Novartis may need to issue an Investigator', 'Notification (IN) to inform all Investigators involved in any study with the same study treatment', 'that this SAE has been reported.', 'Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to', 'the competent authorities and relevant ethics committees in accordance with EU Guidance', '2011/C 172/01 or as per national regulatory requirements in participating countries.', '10.1.4', 'Pregnancy reporting', 'To ensure subject safety, each pregnancy occurring after signing the informed consent must be', 'reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be', 'followed up to determine outcome, including spontaneous or voluntary termination, details of', 'the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal', 'and/or newborn complications.', 'Pregnancy should be recorded and reported by the Investigator to the Novartis Chief Medical', 'Office and Patient Safety. Pregnancy follow-up should be recorded on the same form and should', 'include an assessment of the possible relationship to the study treatment any pregnancy outcome.', 'Any SAE experienced during pregnancy must be reported.', '10.1.5', 'Reporting of study treatment errors including misuse/abuse', 'Medication errors are unintentional errors in the prescribing, dispensing, administration or', 'monitoring of a medicine while under the control of a healthcare professional, subject or', 'consumer (EMA definition).', 'Misuse refers to situations where the medicinal product is intentionally and inappropriately used', 'not in accordance with the protocol.', 'Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product,', 'which is accompanied by harmful physical or psychological effects.']['Novartis', 'Confidential', 'Page 51', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on', 'the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to', 'Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the', 'safety database irrespective of it being associated with an AE/SAE within 24 hours of', \"Investigator's awareness.\", 'Table 10-1', 'Guidance for capturing the study treatment errors including', 'misuse/abuse', 'Treatment error type', 'Document in Dose', 'Document in AE eCRF', 'Complete SAE form', 'Administration Record', '(DAR) eCRF (Yes/No)', 'Unintentional study', 'Yes', 'Only if associated with an', 'Only if associated with an', 'treatment error', 'AE', 'SAE', 'Misuse/Abuse', 'Yes', 'Yes', 'Yes, even if not associated', 'with a SAE', 'For more information on AE and SAE definition and reporting requirements, please see the,', 'respective sections.', '10.2', 'Additional Safety Monitoring', '10.2.1', 'Liver safety monitoring', 'To ensure subject safety and enhance reliability in determining the hepatotoxic potential of an', 'investigational drug, a standardized process for identification, monitoring and evaluation of', 'liver events has to be followed.', 'The following two categories of abnormalities / adverse events have to be considered during', 'the course of the study (irrespective of whether classified/reported as AE/SAE):', 'Liver laboratory triggers, which will require repeated assessments of the abnormal', 'laboratory parameter', 'Liver events, which will require close observation, follow-up monitoring and contributing', 'factors are recorded on the appropriate CRFs', 'Please refer to Table 16-1 - Appendix 2 in Section 16 for complete definitions of liver', 'laboratory triggers and liver events.', 'Every liver event defined in Section 16.1 - Appendix 2 should be followed up by the', 'Investigator or designated personnel at the trial site, as summarized below. Additional details', 'on actions required in case of liver events are outlined in Table 16-2 - Appendix 2. Repeat liver', 'function test (LFT) to confirm elevation.', 'These liver chemistry repeats will be performed using the central laboratory. If results will', 'not be available from the central laboratory, then the repeats can also be performed at a', 'local laboratory to monitor the safety of the subject. If a liver event is subsequently', 'reported, any local liver chemistry tests previously conducted that are associated with this', 'event should have results recorded on the appropriate CRF.', 'If the initial elevation is confirmed, close observation of the subject will be initiated,', 'including consideration of treatment interruption if deemed appropriate.']\n\n###\n\n", "completion": "END"}